Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Non-Current Liabilities (2018 - 2023)

China Pharma Holdings' Other Non-Current Liabilities history spans 10 years, with the latest figure at $2.2 million for Q1 2023.

  • For Q1 2023, Other Non-Current Liabilities changed N/A year-over-year to $2.2 million; the TTM value through Mar 2023 reached $2.2 million, changed N/A, while the annual FY2022 figure was $2.4 million, 26.85% up from the prior year.
  • Other Non-Current Liabilities reached $2.2 million in Q1 2023 per CPHI's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.1 million in Q2 2021 to a low of $1.7 million in Q3 2021.
  • Average Other Non-Current Liabilities over 5 years is $2.3 million, with a median of $2.4 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 31.44% in 2021, then increased 26.85% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $2.4 million in 2019, then grew by 14.44% to $2.7 million in 2020, then plummeted by 31.44% to $1.9 million in 2021, then grew by 26.85% to $2.4 million in 2022, then dropped by 9.15% to $2.2 million in 2023.
  • Per Business Quant, the three most recent readings for CPHI's Other Non-Current Liabilities are $2.2 million (Q1 2023), $2.4 million (Q4 2022), and $1.9 million (Q4 2021).